
Discovery on Target Online Newsroom
Welcome to the Discovery on Target Online Newsroom, your resource for press releases, news coverage, and more. Members of the press looking to cover Discovery on Target are invited to apply for a press pass here.
2025 News
Pharma Companies Finding Their Way with AI
July 15, 2025 | BIO IT WORLD NEWS
AI in Medicine Making and Healthcare: Finding the Balance
August 12, 2025 | BIO IT WORLD NEWS
2019 Interviews
Interview: How Paratope Refinement Can Mitigate Antibody Polyspecificity
JULY 3, 2019 | BIO IT WORLD NEWS
Jonny Finlay, PhD, CSO, Ultrahuman, United Kingdom
Finlay discusses the role of polyspecificity in the toxicity and side effects of checkpoint inhibitors, the solvability of the problem, and where bottlenecks occur during the development stage of biotherapeutic R&D
Interview: Tackling the Clinical and Preclinical Progress in Targeting Membrane Proteins
JUNE 24, 2019 | BIO IT WORLD NEWS
Catherine Hutchings, PhD, Independent Consultant, United Kingdom
Hutchings describes her work tracking the progress in developing biotherapeutics against GPCR and ion channel targets, the successes and failures of targeting membrane proteins, and what technologies in the R&D space have the potential to be game changers.
Interview: Why inhibit Ketohexokinase (KHK) to treat NASH?
MARCH 6, 2019 | DISCOVERY ON TARGET
Kendra K. Bence, PhD, Senior Director, Metabolism, Internal Medicine Research Unit (IMRU), Pfizer, Inc.
Dr. Bence explains why and how Pfizer scientists developed an inhibitor against ketohexokinase as a drug candidate for non-alcoholic steatohepatitis (NASH), a form of liver fibrosis.

Whitepaper: Leveraging Years of Data on GPCRs for Transformative Drug Discovery
2019 | DIAGNOSTICS WORLD NEWS
GPCRs, which play a role in most biological processes, remain one of the most vibrant fields for drug discovery. Years of data are increasingly being leveraged to overcome the complexity of GPCR biology and pharmacology and accelerate GPCR drug discovery. It is now possible to hope to rationally design drugs with optimal effects, thanks to a better understanding of the concept of functional selectivity.